Cellular Intelligence, a rapidly emerging biotech startup formerly known as Somite AI, has secured global rights to a clinical-stage Parkinson’s…
Read More
How CTF is trying to rescue pharma’s shelved rare disease drugs
Across the global pharmaceutical landscape, an estimated 5,000 potential treatments for rare diseases are currently languishing on corporate shelves, representing…
Read More
How CTF is trying to rescue pharma’s shelved rare disease drugs
Across the global pharmaceutical landscape, a staggering number of potentially life-changing therapies for rare diseases lie dormant, gathering dust on…
Read MoreHow CTF is trying to rescue pharma’s shelved rare disease drugs
More than 5,000 potentially life-changing treatments for rare diseases are currently languishing on pharmaceutical company shelves, representing a vast reservoir…
Read More
Novo Nordisk hands a Parkinson’s cell therapy to Cellular Intelligence, a startup trying to design cell behavior
Cellular Intelligence, a burgeoning biotechnology firm formerly known as Somite AI, has announced a significant strategic acquisition, securing global rights…
Read More
Novo Nordisk hands a Parkinson’s cell therapy to Cellular Intelligence, a startup trying to design cell behavior
Cellular Intelligence, a rapidly emerging biotech firm previously known as Somite AI, has secured global rights to a pioneering clinical-stage…
Read More
Novo Nordisk Hands a Parkinson’s Cell Therapy to Cellular Intelligence, a Startup Trying to Design Cell Behavior
In a significant move poised to reshape the landscape of Parkinson’s disease treatment and the broader cell therapy sector, Cellular…
Read More
Novo Nordisk hands a Parkinson’s cell therapy to Cellular Intelligence, a startup trying to design cell behavior
Cellular Intelligence, a burgeoning biotech startup, has announced the acquisition of global rights to a clinical-stage Parkinson’s disease cell therapy,…
Read More
